Take 24 first imitation 2020 generic drugs approved TOP10 enterprises out of the oven

Pharmaceutical Network January 5th, 2020 is about to end, this year, a number of domestic pharmaceutical companies will cross the line, take a number of heavy generic drugs.
as of December 31, NMPA had approved 689 generic drug approvals (in the 3/4/6 category of imitations), involving 240 varieties, according to the company.com.
statistics, in 2020, China's biopharmaceutical, Qilu Pharmaceuticals and Colum Pharmaceuticals ranked in the top three, the number of approved varieties are 23, 17 and 15 respectively.
Yangzijiang Pharmaceutical Group, Dongsian Pharmaceuticals ranked fourth, all 13 varieties were approved; Stone Pharmaceuticals Group has 9 varieties approved; Huahai Pharmaceuticals, Beite Pharmaceuticals have 8 varieties approved; Howson Pharmaceuticals, Yuandong Bio and People's Fu Pharmaceuticals each have 6 varieties approved.
11 pharmaceutical companies approved generic drugs, a total of 24 varieties for the domestic first imitation.
2020 domestic generic drugs approved TOP10 enterprise source: Minet MED2.0 China's drug review database "first imitation king" 23 varieties lead, Zheng Tianqing won 7 first imitation 2020, China Biopharmaceuticals a total of 23 generic drugs (31 regulations) were approved for listing, the total number of the first.
addition to the sodium chloride injection of moxisacin hydrochloric acid and the injection of converted sugar, the remaining varieties were approved according to the newly registered classification, as follows, through consistency evaluation.
The most eye-catching is that 23 varieties of the "first three imitations" accounted for the majority, the first imitation of the domestic 7, respectively, Zhengda Tianqing Pharmaceutical Group's fluvis group injection, Dabiga group ester capsules, Pomadamide capsules, inhalation with Budinide mixed suspension, Entourtabintin Nofowe tablets, phosphate siglitatin tablets and Nanjing Zhengda sunny Omeishatan ammonia tablets.
addition, 5 varieties for the domestic 2nd, 3 varieties for the domestic 3rd.
as the "king of the first imitation", China Biopharmaceuticals since 2015 has been striving for "top three imitations", constantly challenging the difficult to imitate drugs.
years after actively expanding product pipelines, the company by virtue of the early accumulation of excellent capital conditions and the original research patent expiration of the keen pre-judgment many times to take the heavyweight first generic drugs.
that the company expects to have 30 varieties approved each year for the next three years.
17 varieties, this injection has been strong this year, Qilu pharmaceutical products have been approved, the news of evaluation continues.
2020, a total of 17 generic drugs (33 regulations) have been approved for the market, an increase of 4 varieties from 2019.
17 varieties were approved according to the newly registered classification, as follows by the adoption of a consistent evaluation.
, aripitan capsules, cypressili capsules for the domestic first imitation, and cypressili capsules for the first domestic CDK4/6 inhibitors.
17 varieties have 3 injections, namely, pyrithione dnaturna, Osali platinum injection and injection bivaldide, of which Oshali platinum injection is the exclusive evaluation of Qilu Pharmaceuticals.
Osari platinum is a third-generation platinum anti-tumor drug, Qilu Pharmaceuticals' Oshali platinum injection was approved by the U.S. FDA in June 2016 and listed as a participating agent in the U.S. Orange Book, and was announced as a domestic ginseng preparation in May 2020.
Koren took 15 varieties, the product line into the harvest period 2020 to date, Colum Pharmaceuticals a total of 15 generic drugs (24 regulations) were approved for the market, of which 12 varieties with a new registered classification was approved, as if through a consistent evaluation.
Among them, hydrochloric acid valdi na non-slice, compound amino acid (16AA-II.)/glucose (48%) electrolyte injection for the domestic first imitation
of heavyweight generics approved this year is significant for Colum Pharmaceuticals.
Among them, the approval of products such asacid tofatin tablets, hydrochloric acid dapoxitin tablets, hydrochloric acid valdina non-tablets, Ngre net tablets, etc., marks that the generic drugs of Colum Pharmaceuticals have substantially entered the field of autoimmune, male, diabetes and other major diseases;
generics are the basis of Colum Pharmaceuticals' research and development strategy, and the company has laid out a huge pipeline of generic products, covering general injections and infusion drugs, common oral preparations, complex generics and other fields.
that in the next three years, Colum Pharmaceuticals will have more than 70 generic and improved innovative drugs on the market.
13 varieties approved! Yangzijiang, Dongsian Pharmaceuticals ranked fourth 2020 so far, Yangzijiang Pharmaceutical Group, Dongsian Pharmaceuticals have 13 generic drugs approved for market, and ranked fourth.
the same time, the approved varieties of the two enterprises were approved by the new registration classification, as if through the consistent evaluation.
of the 13 generic drugs approved by Yangzijiang Pharmaceutical Group (14 product regulations), Entekave oral solution is the first imitation in China, and Devasaban tablets are the third in China.
Of the 13 generic drugs approved for the East Sunshine Drug (30 product regulations), 4 varieties were the first in China, namely liglitatin tablets, Esomeprazole magnesium intestinal capsules, liglitatin metformin tablets and siglitin metformin tablets.
addition, phosphate siglitin tablets for the domestic 2nd, O nitrogen flat mouth collapse for the domestic 3rd.
data source: Milnet database note: data statistics as of December 31, if there are omissions, welcome to point out!